Soon Young Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Soon Young Park has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Gordon Brent Mills
Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
4 shared publications Dong Zhang
Division of Oncological Sciences, Oregon Health & Science University, Portland, USA
3 shared publications- Alfonso Poire
Division of Oncological Sciences Knight Cancer Institute, Oregon Health and Science University, Portland, USA
2 shared publications Kang Jin Jeong
Division of Oncologic Sciences, Knight Cancer Institute, Oregon Health Sciences University, Portland, USA
2 shared publications- Yiu Huen Tsang
Division of Oncologic Sciences, Knight Cancer Institute, Oregon Health Sciences University, Portland, USA
2 shared publications Alfonso Poire
Department of Cell, Development and Cancer Biology, Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR, USA
1 shared publication
Latest Publications
- Open Access
- 29 September 2026
- Published by Springer Nature in Cellular Oncology
BRD4 is a key regulator of STING expression
- 29 September 2026
- Published by Springer Nature in Cellular Oncology
Open AccessBRD4 is a key regulator of STING expression
- Open Access
- 4 September 2025
- Published by Elsevier in Cancer Letters
- Vol. 633, 218009
Nuclear cGAS mediated replication stress and mitotic catastrophe can overcome gemcitabine resistance
- 4 September 2025
- Published by Elsevier in Cancer Letters
- Vol. 633, 218009
Open AccessNuclear cGAS mediated replication stress and mitotic catastrophe can overcome gemcitabine resistance
- Open Access
- 18 August 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (8) , 1-12
Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer
Ferroptosis, a form of programed cell death, can be promoted by inhibitors of the xCT transporter (erastin) or GPX4 (RSL3). We found that GPX4, but not the xCT transporter, is selectively elevated in luminal breast cancer. Consistent with this observation, the majority of luminal breast cancer cell lines are exquisitely sensitive to RSL3 with limited sensitivity to erastin. In RSL3-resistant, but not sensitive, luminal breast cancer cell lines, RSL3 induces HER2 pathway activation. Irreversible HER2 inhibitors including neratinib reversed RSL3 resistance in constitutively RSL3-resistant cell lines. Combination treatment with RSL3 and neratinib increases ferroptosis through mitochondrial iron-dependent reactive oxygen species production and lipid peroxidation. RSL3 also activated replication stress and concomitant S phase and G2/M blockade leading to sensitivity to targeting the DNA damage checkpoint. Together, our data support the exploration of RSL3 combined with irreversible HER2 inhibitors in clinical trials.
- 18 August 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (8) , 1-12
Open AccessIrreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer
Ferroptosis, a form of programed cell death, can be promoted by inhibitors of the xCT transporter (erastin) or GPX4 (RSL3). We found that GPX4, but not the xCT transporter, is selectively elevated in luminal breast cancer. Consistent with this observation, the majority of luminal breast cancer cell lines are exquisitely sensitive to RSL3 with limited sensitivity to erastin. In RSL3-resistant, but not sensitive, luminal breast cancer cell lines, RSL3 induces HER2 pathway activation. Irreversible HER2 inhibitors including neratinib reversed RSL3 resistance in constitutively RSL3-resistant cell lines. Combination treatment with RSL3 and neratinib increases ferroptosis through mitochondrial iron-dependent reactive oxygen species production and lipid peroxidation. RSL3 also activated replication stress and concomitant S phase and G2/M blockade leading to sensitivity to targeting the DNA damage checkpoint. Together, our data support the exploration of RSL3 combined with irreversible HER2 inhibitors in clinical trials.
- Open Access
- 24 February 2023
- Published by Springer Nature in Research Square
Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer
Ferroptosis, a form of programed cell death, can be promoted by inhibitors of the xCT transporter (erastin) or GPX4 (RSL3). GPX4, but not the xCT transporter, is selectively elevated in luminal breast cancer. Consistent with this observation, the majority of luminal breast cancer cell lines are exquisitely sensitive to RSL3 with limited sensitivity to erastin. In RSL3 resistant, but not sensitive, luminal breast cancer cell lines, RSL3 induces HER2 pathway activation. Irreversible HER2 inhibitors including neratinib reversed RSL3 resistance in constitutively RSL3-resistant cell lines. Combination treatment with RSL3 and neratinib increases ferroptosis through mitochondrial iron-dependent reactive oxygen species production and lipid peroxidation. RSL3 also activated replication stress and concomitant S phase and G2/M blockade leading to sensitivity to targeting the DNA damage checkpoint. Together, our data supports exploration of RSL3 combined with irreversible HER2 inhibitors in clinical trials.
- 24 February 2023
- Published by Springer Nature in Research Square
Open AccessIrreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer
Ferroptosis, a form of programed cell death, can be promoted by inhibitors of the xCT transporter (erastin) or GPX4 (RSL3). GPX4, but not the xCT transporter, is selectively elevated in luminal breast cancer. Consistent with this observation, the majority of luminal breast cancer cell lines are exquisitely sensitive to RSL3 with limited sensitivity to erastin. In RSL3 resistant, but not sensitive, luminal breast cancer cell lines, RSL3 induces HER2 pathway activation. Irreversible HER2 inhibitors including neratinib reversed RSL3 resistance in constitutively RSL3-resistant cell lines. Combination treatment with RSL3 and neratinib increases ferroptosis through mitochondrial iron-dependent reactive oxygen species production and lipid peroxidation. RSL3 also activated replication stress and concomitant S phase and G2/M blockade leading to sensitivity to targeting the DNA damage checkpoint. Together, our data supports exploration of RSL3 combined with irreversible HER2 inhibitors in clinical trials.